Background/Objectives: To evaluate the effectiveness of curative (chemo)radiotherapy in patients with hypopharyngeal carcinoma and to identify prognostic factors influencing treatment outcomes. Methods: We conducted a retrospective study of 173 consecutive patients, treated with definitive or postoperative (chemo)radiotherapy from 2002 to 2020 [median age 60 years; current/former smokers 95%; UICC stage III/IV 96%]. Radiation therapy was preceded by a radical resection of a primary tumor in 32% of patients. One hundred patients received chemotherapy. Results: The median total dose of radiotherapy achieved was 70 Gy. The five- and ten-year locoregional controls were 63%, and the five- and ten-year distant controls were 77% and 76%, respectively. The five- and ten-year overall survival rates were 24% and 9%, respectively. Conclusions: The results demonstrate the limited effectiveness of curative (chemo)radiotherapy in patients with hypopharyngeal carcinoma with long-term locoregional and distant control of half of the treated patients. The multivariate analysis indicated that initial surgery, chemotherapy, comorbidity score (as assessed by ACE-27), pretreatment tracheostomy, hemoglobin level and initial response to treatment were the strongest prognostic factors in predicting survival. Using these factors, corresponding predictive models were constructed.

1st Faculty of Medicine Charles University Prague 12108 Prague Czech Republic

Department of Otorhinolaryngology Bulovka University Hospital 18001 Prague Czech Republic

Institute of Radiation Oncology Bulovka University Hospital 18081 Prague Czech Republic

Radiophysics Department Bulovka University Hospital 18001 Prague Czech Republic

Zobrazit více v PubMed

Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021;71:209–249. doi: 10.3322/caac.21660. PubMed DOI

Jakobsen K.K., Wingstrand V.L., Jensen J.S., Grønhøj C., Jensen D.H., Karnov K., Agander T.K., Specht L., von Buchwald C. Incidence and survival of hypopharyngeal cancer: A Danish Nation-Wide Study from 1980 to 2014. Acta Oncol. 2019;58:1570–1576. doi: 10.1080/0284186X.2019.1657585. PubMed DOI

Estève J., Riboli E., Péquignot G., Terracini B., Merletti F., Crosignani P., Ascunce N., Zubiri L., Blanchet F., Raymond L., et al. Diet and cancers of the larynx and hypopharynx: The IARC multi-center study in southwestern Europe. Cancer Causes Control. 1996;7:240–252. doi: 10.1007/BF00051300. PubMed DOI

Lindberg R., Jesse R.H. Treatment of Cervical lymph node metastasis from primary lesions of the oropharynx, supraglottic larynx and hypopharynx. Am. J. Roentgenol. Radium Ther. Nucl. Med. 1968;102:132–137. doi: 10.2214/ajr.102.1.132. PubMed DOI

Merino O.R., Lindberg R.D., Fletcher G.H. An analysis of distant metastases from squamous cell carcinoma of the upper respiratory and digestive tracts. Cancer. 1977;40:145–151. doi: 10.1002/1097-0142(197707)40:1<145::AID-CNCR2820400124>3.0.CO;2-9. PubMed DOI

Marks J.E., Kurnik B., Powers W.E., Ogura J.H. Carcinoma of the pyriform sinus. An analysis of treatment results and patterns of failure. Cancer. 1978;41:1008–1015. doi: 10.1002/1097-0142(197803)41:3<1008::AID-CNCR2820410332>3.0.CO;2-F. PubMed DOI

Department of Veterans Affairs Laryngeal Cancer Study Group Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N. Engl. J. Med. 1991;324:1685–1690. doi: 10.1056/NEJM199106133242402. PubMed DOI

Lefebvre J.L., Andry G., Chevalier D., Luboinski B., Collette L., Traissac L., de Raucourt D., Langendijk J.A. Laryngeal Preservation with induction chemotherapy for hypopharyngeal squamous cell carcinoma: 10-Year results of EORTC trial 24891. Ann. Oncol. 2012;23:2708–2714. doi: 10.1093/annonc/mds065. PubMed DOI PMC

Richard J.M., Sancho-Garnier H., Pessey J.J., Luboinski B., Lefebvre J., Dehesdin D., Stromboni-Luboinski M., Hill C. Randomized trial of induction chemotherapy in larynx carcinoma. Oral Oncol. 1998;34:224–228. doi: 10.1016/S1368-8375(97)00090-0. PubMed DOI

Kuo P., Chen M.M., Decker R.H., Yarbrough W.G., Judson B.L. Hypopharyngeal cancer incidence, treatment, and survival: temporal trends in the United States. Laryngoscope. 2014;124:2064–2069. doi: 10.1002/lary.24651. PubMed DOI

Kim Y.J., Lee R. Surgery vs. radiotherapy for locally advanced hypopharyngeal cancer in the contemporary era: A population-based study. Cancer Med. 2018;7:5889–5900. doi: 10.1002/cam4.1811. PubMed DOI PMC

Rapoport A., Franco E.L. Prognostic factors and relative risk in hypopharyngeal cancer—Related parameters concerning stage, therapeutics and evolution. Rev. Paul. Med. 1993;111:337–343. PubMed

Yanagi T., Shibamoto Y., Ogino H., Baba F., Murai T., Nagai A., Miyakawa A., Sugie C. Definitive Radiotherapy Following Induction Chemotherapy for Hypopharyngeal Cancer: Selecting Candidates for Organ-Preserving Treatment Based on the Response to Induction Chemotherapy. Kurume Med. J. 2016;62:1–8. doi: 10.2739/kurumemedj.MS65003. PubMed DOI

Hall S.F., Groome P.A., Irish J., O’Sullivan B. Towards further understanding of prognostic factors for head and neck cancer patients: The example of hypopharyngeal cancer. Laryngoscope. 2009;119:696–702. doi: 10.1002/lary.20112. PubMed DOI

Homma A., Sakashita T., Oridate N., Suzuki F., Suzuki S., Hatakeyama H., Mizumachi T., Taki S., Fukuda S. Importance of comorbidity in hypopharyngeal cancer. Head Neck. 2010;32:148–153. doi: 10.1002/hed.21158. PubMed DOI

Tanaka H., Takenaka Y., Nakahara S., Hanamoto A., Fukusumi T., Michiba T., Takemoto N., Cho H., Yamamoto M., Yamamoto Y., et al. Age-adjusted Charlson comorbidity index as a prognostic factor of hypopharyngeal cancer treated with chemoradiation therapy. Acta Oto-Laryngol. 2017;137:668–673. doi: 10.1080/00016489.2016.1269946. PubMed DOI

Canaday D.J., Regine W.F., Mohiuddin M., Zollinger W., Machtay M., Lee J., Schultz D., Rudoltz M.S. Significance of pretreatment hemoglobin level in patients with T1 glottic cancer. Radiat. Oncol. Investig. 1999;7:42–48. doi: 10.1002/(SICI)1520-6823(1999)7:1<42::AID-ROI6>3.0.CO;2-W. PubMed DOI

Chung E.-J., Lee J.-J., Kim H.-S., Lee D.-J., Jung C.-H., Chang Y.-J., Rho Y.-S. Alternative treatment option for hypopharyngeal cancer: Clinical outcomes after conservative laryngeal surgery with partial pharyngectomy. Acta Oto-Laryngol. 2013;133:866–873. doi: 10.3109/00016489.2013.785018. PubMed DOI

Milisavljevic D., Stankovic M., Zivic M., Popovic M., Radovanović Z. Factors affecting results of treatment of Hypopharyngeal Carcinoma. Hippokratia. 2009;13:154–160. PubMed PMC

Chang M.F.-T., Wang H.-M., Kang C.-J., Huang S.-F., Lin C.-Y., Fang K.-H., Chen E.Y.-C., Chen I.-H., Liao C.-T., Chang J.T.-C. Treatment results for hypopharyngeal cancer by different treatment strategies and its secondary primary—An experience in Taiwan. Radiat. Oncol. 2010;5:91–98. doi: 10.1186/1748-717X-5-91. PubMed DOI PMC

Yoon M.S., Chung W.K., Ahn S.J., Nam T.K., Song J.Y., Nah B.S., Lim S.C.H., Lee J.K. Treatment Results and prognostic Factors in Locally Advanced Hypopharyngeal Cancer. Radiat. Oncol. J. 2007;25:151–159.

Vengaloor Thomas T., Nittala M.R., Bhanat E., Albert A.A., Vijayakumar S. Management of Advanced-Stage Hypopharyngeal Carcinoma: 25-Year Experience from a Tertiary Care Medical Center. Cureus. 2020;12:e6679. doi: 10.7759/cureus.6679. PubMed DOI PMC

Mochiki M., Sugasawa M., Nibu K., Asai M., Nakao K., Asakage T. Prognostic factors for hypopharyngeal cancer: A univariate and multivariate study of 142 cases. Acta Oto-Laryngol. Suppl. 2007;559:136–144. doi: 10.1080/03655230701600095. PubMed DOI

Shirai K., Saitoh J.I., Musha A., Abe T., Kobayashi D., Takakusagi Y., Takaysu Y., Shino M., Toyoda M., Takahashi K., et al. Clinical Outcomes of Definitive and Postoperative Radiotherapy for Stage I-IVB Hypopharyngeal Cancer. Anticancer Res. 2016;36:6571–6578. doi: 10.21873/anticanres.11261. PubMed DOI

Tsai Y.-T., Chen W.-C., Chien C.-Y., Hsu C.-M., Lee Y.-C., Tsai M.-S., Lin M.-H., Lai C.-H., Chang K.-P. Treatment patterns and survival outcomes of advanced hypopharyngeal squamous cell carcinoma. World J. Surg. Oncol. 2020;18:82. doi: 10.1186/s12957-020-01866-z. PubMed DOI PMC

Kim S.-Y., Rho Y.-S., Choi E.-C., Kim M.-S., Woo J.-H., Lee D.H., Chung E.J., Park M.W., Kim D.-H., Joo Y.-H. Clinicopathological factors influencing the outcomes of surgical treatment in patients with T4a hypopharyngeal cancer. BMC Cancer. 2017;17:904. doi: 10.1186/s12885-017-3880-6. PubMed DOI PMC

Chen T.-C., Wang C., Su L.-Y., Lin M.-C., Yang T.-L., Lou P.-J., Ko J.-Y., Wang C.-P. Impact of invasion into cervical esophagus for patients with hypopharyngeal squamous cell carcinoma. Oral Oncol. 2022;125:105683. doi: 10.1016/j.oraloncology.2021.105683. PubMed DOI

Chen S.W., Yang S.N., Liang J.A., Tsai M.H., Shiau A.C., Lin F.J. Value of computed tomography-based tumor volume as a predictor of outcomes in hypopharyngeal cancer after treatment with definitive radiotherapy. Laryngoscope. 2006;116:2012–2017. doi: 10.1097/01.mlg.0000237804.38761.81. PubMed DOI

Tsou Y.A., Hua J.H., Lin M.H., Tsai M.H. Analysis of prognostic factors of chemoradiation therapy for advanced hypopharyngeal cancer—Does tumor volume correlate with central necrosis and tumor pathology? ORL J. Otorhinolaryngol. Relat. Spec. 2006;68:206–212. doi: 10.1159/000091803. PubMed DOI

Chen S.W., Yang S.N., Liang J.A., Lin F.J., Tsai M.H. Prognostic impact of tumor volume in patients with stage III-IVA hypopharyngeal cancer without bulky lymph nodes treated with definitive concurrent chemoradiotherapy. Head Neck. 2009;31:709–716. doi: 10.1002/hed.21011. PubMed DOI

Baghi M., Bisdas S., Engels K., Yousefi M., Wagenblast J., Hambek M., Knecht R. Prognostic relevance of volumetric analysis in tumour specimens of hypopharyngeal cancer. Clin Otolaryngol. 2007;32:372–377. doi: 10.1111/j.1749-4486.2007.01531.x. PubMed DOI

Martin S.A., Marks J.E., Lee J.Y., Bauer W.C., Ogura J.H. Carcinoma of the pyriform sinus: Predictors of TNM relapse and survival. Cancer. 1980;46:1974–1981. doi: 10.1002/1097-0142(19801101)46:9<1974::AID-CNCR2820460913>3.0.CO;2-A. PubMed DOI

Fan K.H., Yeh C.H., Hung S.P., Kang C.-J., Huang S.-F., Chang K.-P., Wang H.-M., Hsieh J.C.-H., Lin C.-Y., Cheng A.-J., et al. Prognostic value of radiologic extranodal extension in patients with hypopharyngeal cancer treated with primary chemoradiation. Radiother. Oncol. 2021;156:217–222. doi: 10.1016/j.radonc.2020.12.028. PubMed DOI

Lee M.S., Ho H.C., Hsiao S.H., Hwang J.H., Lee C.C., Hung S.K. Treatment results and prognostic factors in locally advanced hypopharyngeal cancer. Acta Oto-Laryngol. 2008;128:103–109. doi: 10.1080/00016480701387116. PubMed DOI

Tang X., Pang T., Yan W.F., Qian W.L., Gong Y.L., Yang Z.G. A novel prognostic model predicting the long-term cancer-specific survival for patients with hypopharyngeal squamous cell carcinoma. BMC Cancer. 2020;20:1095. doi: 10.1186/s12885-020-07599-2. PubMed DOI PMC

Rudat V., Ahmet-Osman S., Schramm O., Dietz A. Definitive Radiotherapy Versus Postoperative Radiotherapy of Patients with Oro- and Hypopharyngeal Cancer: Impact of Prognostic Factors. J. Oncol. 2012;2012:391917. doi: 10.1155/2012/391917. PubMed DOI PMC

Shaughnessy J.N., Farghaly H., Wilson L., Redman R., Potts K., Bumpous J., Silverman C., Dunlap N.E. HPV: A factor in organ preservation for locally advanced larynx and hypopharynx cancer? Am. J. Otolaryngol. 2014;35:19–24. doi: 10.1016/j.amjoto.2013.08.006. PubMed DOI

Burbure N., Handorf E., Ridge J.A., Bauman J., Liu J.C., Giri A., Galloway T.J. Prognostic significance of human papillomavirus status and treatment modality in hypopharyngeal cancer. Head Neck. 2021;43:3042–3052. doi: 10.1002/hed.26793. PubMed DOI PMC

Arends C.R., Petersen J.F., van der Noort V., Timmermans A.J., Leemans C.R., de Bree R., Brekel M.W.v.D., Stuiver M.M. Optimizing Survival Predictions of Hypopharynx Cancer: Development of a Clinical Prediction Model. Laryngoscope. 2020;130:2166–2172. doi: 10.1002/lary.28345. PubMed DOI PMC

Suzuki G., Ogo E., Abe T., Hayabuchi N., Umeno H., Nakashima T., Yamazaki H., Nakamura S., Yoshida K. Non-surgical multimodality treatment for locally advanced (T3-4) hypopharyngeal cancer: The impact of pre-treatment hemoglobin level. Anticancer Res. 2013;33:5561–5565. PubMed

Lo W.-C., Wu C.-T., Wang C.-P., Yang T.-L., Lou P.-J., Ko J.-Y., Chang Y.-L. Lymph Node Ratio Predicts Recurrence and Survival for Patients with Resectable Stage 4 Hypopharyngeal Cancer. Ann. Surg. Oncol. 2017;24:1707–1713. doi: 10.1245/s10434-017-5770-1. PubMed DOI

Cox J.D., Stetz J., Pajak T.F. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) Int. J. Radiat. Oncol. Biol. Phys. 1995;31:1341–1346. doi: 10.1016/0360-3016(95)00060-C. PubMed DOI

Piccirillo J.F., Tierney R.M., Costas I., Grove L., Spitznagel E.L., Jr. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA. 2004;291:2441–2447. doi: 10.1001/jama.291.20.2441. PubMed DOI

Vandenbrouck C., Eschwege F., De la Rochefordiere A., Sicot H., Mamelle G., Le Ridant A.M., Bosq J., Domenge C. Squamous cell carcinoma of the pyriform sinus: Retrospective study of 351 cases treated at the Institut Gustave-Roussy. Head Neck Surg. 1987;10:4–13. doi: 10.1002/hed.2890100103. PubMed DOI

Frank J.L., Garb J.L., Kay S., McClish D.K., Bethke K.P., Lind D.S., Mellis M., Slomka W., Sismanis A., Neifeld J.P. Postoperative radiotherapy improves survival in squamous cell carcinoma of the hypopharynx. Am. J. Surg. 1994;168:476–480. doi: 10.1016/S0002-9610(05)80105-9. PubMed DOI

Iwae S., Fujii M., Hayashi R., Hasegawa Y., Fujii T., Okami K., Homma A., Onitsuka T., Kato T., Ogawa T., et al. Matched-pair analysis of patients with advanced hypopharyngeal cancer: Surgery versus concomitant chemoradiotherapy. Int. J. Clin. Oncol. 2017;22:1001–1008. doi: 10.1007/s10147-017-1151-9. PubMed DOI

Kim J.W., Kim M.S., Kim S.H., Kim J.H., Lee C.G., Kim G.E., Keum K.C. Definitive Chemoradiotherapy Versus Surgery Followed by Adjuvant Radiotherapy in Resectable Stage III/IV Hypopharyngeal Cancer. Cancer Res. Treat. 2016;48:45–53. doi: 10.4143/crt.2014.340. PubMed DOI PMC

Bolner A., Valentini A., Ambrosini G., Amichetti M., Borriello G., Busana L., Fellin G., Graiff C., Nassivera E., Pani G. La radioterapia, la radioterapia associata a chirurgia, la radioterapia associata alla chemioterapia nel trattamento del carcinoma del seno piriforme [Radiotherapy, radiotherapy combined with surgery, radiotherapy combined with chemo-therapy in the treatment of carcinoma of the pyriform sinus. A retrospective study]. Analisi retrospettiva. Radiol. Med. 1991;82:493–499. PubMed

Zelefsky M.J., Kraus D.H., Pfister D.G., Raben A., Shah J.P., Strong E.W., Spiro R.H., Bosl G.J., Harrison L.B. Combined chemotherapy and radiotherapy versus surgery and postoperative radiotherapy for advanced hypopharyngeal cancer. Head Neck. 1996;18:405–411. doi: 10.1002/(SICI)1097-0347(199609/10)18:5<405::AID-HED3>3.0.CO;2-9. PubMed DOI

Johansen L.V., Grau C., Overgaard J. Hypopharyngeal squamous cell carcinoma—Treatment results in 138 consecutively admitted patients. Acta Oncol. 2000;39:529–536. doi: 10.1080/028418600750013465. PubMed DOI

Godballe C., Jørgensen K., Hansen O., Bastholt L. Hypopharyngeal cancer: Results of treatment based on radiation therapy and salvage surgery. Laryngoscope. 2002;112:834–838. doi: 10.1097/00005537-200205000-00011. PubMed DOI

Sakaguchi M., Maebayashi T., Aizawa T., Ishibashi N., Saito T. Clinical Outcomes of Hypopharyngeal Cancer Receiving Definitive Radiotherapy with Concurrent Chemotherapy. Anticancer Res. 2017;37:941–947. doi: 10.21873/anticanres.11403. PubMed DOI

Reis I., Aguiar A., Alzamora C., Ferreira C., Castro V., Soares A., Lobão M. Locally advanced hypopharyngeal squamous cell carcinoma: Single-institution outcomes in a cohort of patients curatively treated either with or without larynx preservation. Radiol. Bras. 2016;49:21–25. doi: 10.1590/0100-3984.2015.0018. PubMed DOI PMC

Chen Y.Y., Tsai Y.T., Tsai M.S., Hsu C.M., Lai C.H., Lu C.H., Chen P.T., Fang F.M., Chen M.F., Chen W.C. Treatment outcomes of locally advanced hypopharyngeal squamous cell carcinoma. Ther. Radiol. Oncol. 2018;2:17. doi: 10.21037/tro.2018.03.02. DOI

Hall S.F., Groome P.A., Irish J., O’Sullivan B. Radiotherapy or surgery for head and neck squamous cell cancer: Establishing the baseline for hypopharyngeal carcinoma? Cancer. 2009;115:5711–5722. doi: 10.1002/cncr.24635. PubMed DOI

Harris B.N., Biron V.L., Donald P., Farwell D.G., Luu Q.C., Bewley A.F., Chen A.M., Daly M.E. Primary Surgery vs Chemoradiation Treatment of Advanced-Stage Hypopharyngeal Squamous Cell Carcinoma. JAMA Otolaryngol. Head Neck Surg. 2015;141:636–640. doi: 10.1001/jamaoto.2015.0659. PubMed DOI

Petersen J., Arends C., van der Noort V., Al-Mamgani A., de Boer J., Stuiver M., Brekel M.v.D. Laryngo-esophageal dysfunction free survival and propensity score matched analysis comparing organ preservation and total laryngectomy in hypopharynx cancer. Oral Oncol. 2019;95:143–149. doi: 10.1016/j.oraloncology.2019.06.018. PubMed DOI

García-Cabo P., López F., Sánchez-Canteli M., Fernández-Vañes L., Álvarez-Marcos C., Llorente J.L., de la Rúa M.Á., Blay P., Rodrigo J.P. Matched-Pair Analysis of Survival in the Patients with Advanced Laryngeal and Hypopharyngeal Squamous Cell Carcinoma Treated with Induction Chemotherapy Plus Chemo-Radiation or Total Laryngectomy. Cancers. 2021;13:1735. doi: 10.3390/cancers13071735. PubMed DOI PMC

Dietz A., Wichmann G., Kuhnt T., Pfreundner L., Hagen R., Scheich M., Kölbl O., Hautmann M., Strutz J., Schreiber F., et al. Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal/hypopharyngeal cancer resectable only by total laryngectomy-final results of the larynx organ preservation trial DeLOS-II. Ann. Oncol. 2018;29:2105–2114. doi: 10.1093/annonc/mdy332. PubMed DOI

Panda S., Sakthivel P., Gurusamy K.S., Sharma A., Thakar A. Treatment options for resectable hypopharyngeal squamous cell carcinoma: A systematic review and meta-analysis of randomized controlled trials. PLoS ONE. 2022;17:e0277460. doi: 10.1371/journal.pone.0277460. PubMed DOI PMC

Beauvillain C., Mahé M., Bourdin S., Peuvrel P., Bergerot P., Rivière A., Vignoud J., Deraucourt D., Wesoluch M. Final results of a randomized trial comparing chemotherapy plus radiotherapy with chemotherapy plus surgery plus radiotherapy in locally advanced resectable hypopharyngeal carcinomas. Laryngoscope. 1997;107:648–653. doi: 10.1097/00005537-199705000-00017. PubMed DOI

Tsou Y.-A., Lin M.-H., Hua C.-H., Tseng H.-C., Chen S.-W., Yang S.-N., Liang J.-A., Tsai M.-H. Survival outcome by early chemoradiation therapy salvage or early surgical salvage for the treatment of hypopharyngeal cancer. Otolaryngol. Head Neck Surg. 2007;137:711–716. doi: 10.1016/j.otohns.2007.07.022. PubMed DOI

Cui J., Wang L., Piao J., Huang H., Chen W., Chen Z., Yang H., Tan X., Li J., Liu G. Initial surgical versus non-surgical treatments for advanced hypopharyngeal cancer: A meta-analysis with trial sequential analysis. Int. J. Surg. 2020;82:249–259. doi: 10.1016/j.ijsu.2020.04.059. PubMed DOI

Fan J.M., Wen S.X., Wang B.Q., Huangfu H., Zhai X.S., Zhao X.J. Meta-analysis of comparison for efficacies between surgical plus radio(chemo)therapy and non-surgery chemoradiotherapy treatment strategies for advanced hypopharyngeal cancer. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2020;55:144–149. doi: 10.3760/cma.j.issn.1673-0860.2020.02.011. PubMed DOI

Tsai T.Y., Yap W.K., Wang T.H., Lu Y.A., See A., Hu Y.F., Huang Y., Kao H.K., Chang K.P. Upfront Surgery Versus Upfront Concurrent Chemoradiotherapy as Primary Modality in Hypopharyngeal Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis. J. Otolaryngol. Head Neck Surg. 2024;53:19160216241293633. doi: 10.1177/19160216241293633. PubMed DOI PMC

Pignon J.-P., le Maître A., Maillard E., Bourhis J., MACH-NC Collaborative Group Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. Radiother. Oncol. 2009;92:4–14. doi: 10.1016/j.radonc.2009.04.014. PubMed DOI

Bernier J., Domenge C., Ozsahin M., Matuszewska K., Lefèbvre J.-L., Greiner R.H., Giralt J., Maingon P., Rolland F., Bolla M., et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N. Engl. J. Med. 2004;350:1945–1952. doi: 10.1056/NEJMoa032641. PubMed DOI

Cooper J.S., Pajak T.F., Forastiere A.A., Jacobs J., Campbell B.H., Saxman S.B., Kish J.A., Kim H.E., Cmelak A.J., Rotman M., et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 2004;350:1937–1944. doi: 10.1056/NEJMoa032646. PubMed DOI

Boehm A., Lindner F., Wichmann G., Bauer U., Wittekind C., Knoedler M., Lordick F., Dietzsch S., Scholz M., Kortmann R., et al. Impact of indication-shift of primary and adjuvant chemo radiation in advanced laryngeal and hypopharyngeal squamous cell carcinoma. Eur. Arch. Oto-Rhino-Laryngol. 2015;272:2017–2025. doi: 10.1007/s00405-014-3134-z. PubMed DOI

Prades J.-M., Lallemant B., Garrel R., Reyt E., Righini C., Schmitt T., Remini N., Saban-Roche L., Timoshenko A.P., Trombert B., et al. Randomized phase III trial comparing induction chemotherapy followed by radiotherapy to concomitant chemoradiotherapy for laryngeal preservation in T3M0 pyriform sinus carcinoma. Acta Oto-Laryngol. 2010;130:150–155. doi: 10.3109/00016480902914080. PubMed DOI

Bensadoun R.-J., Bénézery K., Dassonville O., Magné N., Poissonnet G., Ramaïoli A., Lemanski C., Bourdin S., Tortochaux J., Peyrade F., et al. French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: Results at 2 years (FNCLCC-GORTEC) Int. J. Radiat. Oncol. Biol. Phys. 2006;64:983–994. doi: 10.1016/j.ijrobp.2005.09.041. PubMed DOI

Paximadis P., Yoo G., Lin H.-S., Jacobs J., Sukari A., Dyson G., Christensen M., Kim H. Concurrent chemoradiotherapy improves survival in patients with hypopharyngeal cancer. Int. J. Radiat. Oncol. Biol. Phys. 2012;82:1515–1521. doi: 10.1016/j.ijrobp.2011.04.064. PubMed DOI PMC

Bøje C.R., Dalton S.O., Primdahl H., Kristensen C.A., Andersen E., Johansen J., Andersen L.J., Overgaard J. Evaluation of comorbidity in 9388 head and neck cancer patients: A national cohort study from the DAHANCA database. Radiother. Oncol. 2014;110:91–97. doi: 10.1016/j.radonc.2013.11.009. PubMed DOI

Monteiro A.R., Garcia A.R., Pereira T.C., Macedo F., Soares R.F., Pereira K., Serra T., Khouri L., Ribeiro J., Teixeira M.M. ACE-27 as a prognostic tool of severe acute toxicities in patients with head and neck cancer treated with chemoradiotherapy: A real-world, prospective, observational study. Support. Care Cancer. 2021;29:1863–1871. doi: 10.1007/s00520-020-05679-4. PubMed DOI

Molls M., Stadler P., Becker A., Feldmann H.J., Dunst J. Relevance of oxygen in radiation oncology. Mechanisms of action, correlation to low hemoglobin levels. Strahlenther. Onkol. 1998;174(Suppl. 4):13–16. PubMed

Feldmann H.J., Molls M., Vaupel P. Blood flow and oxygenation status of human tumors. Clinical investigations. Strahlenther. Onkol. 1999;175:1–9. doi: 10.1007/BF02743452. PubMed DOI

Evans S.M., Jenkins W.T., Shapiro M., Koch C.J. Evaluation of the concept of “hypoxic fraction” as a descriptor of tumor oxygenation status. Adv. Exp. Med. Biol. 1997;411:215–225. doi: 10.1007/978-1-4615-5865-1_26. PubMed DOI

Teicher B.A. Physiologic mechanisms of therapeutic resistance. Blood flow and hypoxia. Hematol./Oncol. Clin. N. Am. 1995;9:475–506. doi: 10.1016/S0889-8588(18)30105-9. PubMed DOI

Jund R., Feldmann H.J., Wollenberg B., Stadler P., Molls M. Changes in head and neck tumor hypoxic fraction during split-course radiochemotherapy. Ann. Otol. Rhinol. Laryngol. 1999;108:73–78. doi: 10.1177/000348949910800111. PubMed DOI

Harrison L.B., Chadha M., Hill R.J., Hu K., Shasha D. Impact of tumor hypoxia and anemia on radiation therapy outcomes. Oncologist. 2002;7:492–508. doi: 10.1634/theoncologist.7-6-492. PubMed DOI

Okunieff P., de Bie J., Dunphy E.P., Terris D.J., Höckel M. Oxygen distributions partly explain the radiation response of human squamous cell carcinomas. Br. J. Cancer Suppl. 1996;27:S185–S190. PubMed PMC

Dietz A., Rudat V., Vanselow B., Wollensack P., Bettscheider C., Conradt C., Eble M.J. Rise of oxygenation in cervical lymph node metastasis during the initial course of radiochemotherapy. Otolaryngol. Head Neck Surg. 1999;121:789–796. doi: 10.1053/hn.1999.v121.a91545. PubMed DOI

Kondo A., Safaei R., Mishima M., Niedner H., Lin X., Howell S.B. Hypoxia-induced enrichment and mutagenesis of cells that have lost DNA mismatch repair. Cancer Res. 2001;61:7603–7607. PubMed

Yuan J., Glazer P.M. Mutagenesis induced by the tumor microenvironment. Mutat. Res. 1998;400:439–446. doi: 10.1016/S0027-5107(98)00042-6. PubMed DOI

Johansen L.V., Grau C., Overgaard J. Laryngeal carcinoma--multivariate analysis of prognostic factors in 1252 consecutive patients treated with primary radiotherapy. Acta Oncol. 2003;42:771–778. doi: 10.1080/02841860310017595. PubMed DOI

Rutkowski T., Suwinski R., Idasiak A. The prognostic value of hemoglobin concentration in postoperative radiotherapy of 835 patients with laryngeal cancer. Int. J. Radiat. Oncol. Biol. Phys. 2007;69:1018–1023. doi: 10.1016/j.ijrobp.2007.04.064. PubMed DOI

Wagner W., Hermann R., Hartlapp J., Esser E., Christoph B., Müller M.K., Krech R., Koch O. Prognostic value of hemoglobin concentrations in patients with advanced head and neck cancer treated with combined radio-chemotherapy and surgery. Strahlenther. Onkol. 2000;176:73–80. doi: 10.1007/PL00002331. PubMed DOI

Tarnawski R., Skladowski K., Maciejewski B. Prognostic value of hemoglobin concentration in radiotherapy for cancer of supraglottic larynx. Int. J. Radiat. Oncol. Biol. Phys. 1997;38:1007–1011. doi: 10.1016/S0360-3016(97)00308-8. PubMed DOI

Fein D.A., Lee W.R., Hanlon A.L., A Ridge J., Langer C.J., Curran W.J., Coia L.R. Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx. J. Clin. Oncol. 1995;13:2077–2083. doi: 10.1200/JCO.1995.13.8.2077. PubMed DOI

Fukada J., Shigematsu N., Takeda A., Ohashi T., Tomita T., Shiotani A., Kunieda E., Kawaguchi O., Fujii M., Kubo A. Weekly low-dose docetaxel-based chemoradiotherapy for locally advanced oropharyngeal or hypopharyngeal carcinoma: A retrospective, single-institution study. Int. J. Radiat. Oncol. Biol. Phys. 2010;76:417–424. doi: 10.1016/j.ijrobp.2009.01.056. PubMed DOI

Mendenhall W.M., Parsons J.T., Stringer S.P., Cassisi N.J., Million R.R. Stage T3 squamous cell carcinoma of the glottic larynx: A comparison of laryngectomy and irradiation. Int. J. Radiat. Oncol. Biol. Phys. 1992;23:725–732. doi: 10.1016/0360-3016(92)90644-W. PubMed DOI

Chiesa Estomba C.M., Betances Reinoso F.A., Martinez Villasmil V., González Cortés M.J., Santidrian Hidalgo C. Persistent Tracheostomy after Organ Preservation Protocol in Patients Treated for Larynx and Hypopharynx Cancer. Int. Arch. Otorhinolaryngol. 2017;21:377–381. doi: 10.1055/s-0037-1601416. PubMed DOI PMC

MacKenzie R., Franssen E., Balogh J., Birt D., Gilbert R. The prognostic significance of tracheostomy in carcinoma of the larynx treated with radiotherapy and surgery for salvage. Int. J. Radiat. Oncol. Biol. Phys. 1998;41:43–51. doi: 10.1016/S0360-3016(98)00030-3. PubMed DOI

Herchenhorn D., Dias F.L., Ferreira C.G., Araújo C.M., Lima R.A., Small I.A., Kligerman J. Impact of previous tracheotomy as a prognostic factor in patients with locally advanced squamous cell carcinoma of the larynx submitted to concomitant chemotherapy and radiation. ORL J. Otorhinolaryngol. Relat. Spec. 2008;70:381–388. doi: 10.1159/000163034. PubMed DOI

Tennant P.A., Cash E., Bumpous J.M., Potts K.L. Persistent tracheostomy after primary chemoradiation for advanced laryngeal or hypopharyngeal cancer. Head Neck. 2014;36:1628–1633. doi: 10.1002/hed.23508. PubMed DOI